Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 360 of 360 entries
View as:

A Safety, Tolerability and Efficacy Study of E7070 in Patients With Renal Cell Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT00059735 Org: User:
Start: 05/31/02 End: 12/31/03 Due: 12/31/04

A Study to Evaluate the Pharmacokinetics of E2609 and Its Metabolites in Subjects With Mild and Moderate Hepatic Impairment Compared With Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT02859207 Org: User:
Start: 08/31/16 End: 01/25/17 Due: 01/25/18

A Pharmacokinetic Study to Assess the Influence of Simultaneous CYP3A4 and P-glycoprotein Inhibition on E7080 Pharmacokinetics Following Single Dose Oral Administration of 5 mg E7080 to Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT02198170 Org: User:
Start: 02/28/11 End: 06/30/11 Due: 06/30/12

BLOOM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management

Phase: N/A Priority: Normal
NCT ID: NCT00395135 Org: User:
Start: 11/30/06 End: 02/28/09 Due: 02/28/10

A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of E6201 in Subjects With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT00794781 Org: User:
Start: 06/22/08 End: 10/15/15 Due: 10/15/16

Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (HCl) (Aricept) In Treating Cognitive Dysfunction Exhibited By Children With Down Syndrome

Phase: N/A Priority: Normal
NCT ID: NCT00570128 Org: User:
Start: 11/16/07 End: 09/05/08 Due: 09/05/09

Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome, Aged 11 To 17

Phase: N/A Priority: Normal
NCT ID: NCT00754052 Org: User:
Start: 09/30/08 End: 12/31/08 Due: 12/31/09

A Study of E3810 With Pre- and Post-Treatment pH Monitoring in Patients With Non-Erosive Gastroesophageal Reflux Disease

Phase: N/A Priority: Normal
NCT ID: NCT00165672 Org: User:
Start: 05/31/05 End: 10/31/05 Due: 10/31/06

FOLFIRI Alone Versus FOLFIRI Plus Bevacizumab Versus FOLFIRI Plus E7820 as Second-Line Therapy in Patients With Locally Advanced or Metastatic Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01133990 Org: User:
Start: 03/04/10 End: 02/18/11 Due: 02/18/12

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of E2730 in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT03451890 Org: User:
Start: 02/09/18 End: 09/26/18 Due: 09/26/19